JP2025513714A - Ｃｄ３に特異的な脱免疫抗体 - Google Patents

Ｃｄ３に特異的な脱免疫抗体 Download PDF

Info

Publication number
JP2025513714A
JP2025513714A JP2024556078A JP2024556078A JP2025513714A JP 2025513714 A JP2025513714 A JP 2025513714A JP 2024556078 A JP2024556078 A JP 2024556078A JP 2024556078 A JP2024556078 A JP 2024556078A JP 2025513714 A JP2025513714 A JP 2025513714A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513714A5 (enExample
Inventor
ムースメイヤー，マーカス
ブルトマン，アンドレアス
ルンツ，シュテファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of JP2025513714A publication Critical patent/JP2025513714A/ja
Publication of JP2025513714A5 publication Critical patent/JP2025513714A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024556078A 2022-03-22 2023-03-21 Ｃｄ３に特異的な脱免疫抗体 Pending JP2025513714A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22163663.2 2022-03-22
EP22163663 2022-03-22
PCT/EP2023/057248 WO2023180346A1 (en) 2022-03-22 2023-03-21 Deimmunized antibodies specific for cd3

Publications (2)

Publication Number Publication Date
JP2025513714A true JP2025513714A (ja) 2025-04-30
JP2025513714A5 JP2025513714A5 (enExample) 2026-05-12

Family

ID=80930505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556078A Pending JP2025513714A (ja) 2022-03-22 2023-03-21 Ｃｄ３に特異的な脱免疫抗体

Country Status (9)

Country Link
US (1) US20250206819A1 (enExample)
EP (1) EP4496812A1 (enExample)
JP (1) JP2025513714A (enExample)
KR (1) KR20240158351A (enExample)
CN (1) CN118922448A (enExample)
AU (1) AU2023240297A1 (enExample)
CA (1) CA3246381A1 (enExample)
IL (1) IL315591A (enExample)
WO (1) WO2023180346A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
WO2025106469A1 (en) * 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
AU2003236728A1 (en) 2002-06-10 2003-12-22 Algonomics N.V. Method for predicting the binding affinity of mhc/peptide complexes
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
HRP20181811T1 (hr) 2010-11-19 2018-12-28 Morphosys Ag Zbirka sljedova protutijela i njezina upotreba
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
ES2742224T3 (es) * 2013-11-07 2020-02-13 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos anti-WT1/HLA
RU2016151235A (ru) * 2014-05-28 2018-06-28 Ф. Хоффманн-Ля Рош Аг Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус
US11472880B2 (en) * 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
CA3121699A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules

Also Published As

Publication number Publication date
CA3246381A1 (en) 2023-09-28
US20250206819A1 (en) 2025-06-26
AU2023240297A1 (en) 2024-10-03
EP4496812A1 (en) 2025-01-29
IL315591A (en) 2024-11-01
CN118922448A (zh) 2024-11-08
WO2023180346A1 (en) 2023-09-28
KR20240158351A (ko) 2024-11-04

Similar Documents

Publication Publication Date Title
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
JP7530299B2 (ja) 抗ｃｄ３抗体及びその使用
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
US11472880B2 (en) Humanized antibodies for CD3
RU2727914C2 (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2021502100A (ja) 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
TW202227491A (zh) 抗ｒｏｒ１抗體及相關雙特異性結合蛋白
JP2019535650A (ja) ヘテロダイマー免疫グロブリン構造体及びその製造方法
TW202241956A (zh) 新穎抗cd24抗體
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
JP7851303B2 (ja) ヒトｃｄ３イプシロンに結合する新規なヒト抗体
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
IL302412A (en) Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
JP2024516098A (ja) Ｂｃｍａを標的とする多重特異性抗体
US20250206819A1 (en) Deimmunized antibodies specific for cd3
JP2026507108A (ja) Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及びその医薬的使用
US20250163182A1 (en) Enpp3 and cd3 binding agents and methods of use thereof
JP2025521496A (ja) Ｃｄ１１７を標的とする抗体
JP7595195B2 (ja) ヒトインターロイキン－４受容体アルファ抗体グルココルチコイドコンジュゲート
US12304958B2 (en) Antibodies targeting ActRIIA and ActRIIB
TW202436345A (zh) 抗ｃｄ３多特異性抗體及使用方法
EA045935B1 (ru) Антитела к cd3 и их применение

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260428